Overview

A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients

Status:
Active, not recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

Primary objective: - To evaluate the disease-free survival (DFS) in the two randomized arms after therapy with LC vs. EC in chemo-naive Her2-patients with stage I or II breast cancer Secondary objectives: - To assess the overall survival (OS) - To establish the safety profile by assessing the toxicities and tolerability - To assess the quality of life (QoL) - To evaluate survival correlation with biomarkers expression.

Phase:

Phase 2

Details

Lead Sponsor:

TTY Biopharm

Treatments:

Cyclophosphamide
Doxorubicin
Epirubicin
Liposomal doxorubicin